Purchase this article with an account.
T. Ito, K. Hijioka, T. Fujimoto, K.-H. Sonoda, T. Ishibashi; The Effectiveness of Infliximab for Refractory Uveitis Due to Behcet’S Disease. Invest. Ophthalmol. Vis. Sci. 2009;50(13):6026.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
Infliximab is an anti-tumor necrosis factor-alpha (TNF-) antibody, and has been used for the treatment of Crohn disease and rheumatoid arthritis. It is known that serum concentration of TNF- is elevated in patients with Behcet’s disease (BD) . Infliximab is officially approved for the treatment of refractory uveitis due to BD in Japan since January 2007. We herein report the effectiveness of Infliximab against ocular BD.
Retrospective evaluation of 18 BD patients with refractory uveitis despite under the treatment of colchicine and/or cyclosporine at Kyushu University. They were treated by Infliximab at a dose of 5mg/kg in a single intravenous infusinon on zero, two weeks, six weeks, and every eight weeks. Patients were all male and the mean age was 40.7 years old. The main outcome measures were the number of uveitis attack, visual acuity, and systemic side effects.
The mean follow-up period was 15 months (range: 2-25 months). In all patients, the frequency and seriousness of uveitis attack was decreased remarkably, and in four patients, uveitis attack was not caused at all. The extra-ocular symptoms were also improved. So far, we have not observed systemic severe side effects.
Infliximab is effective and safe for refractory uveitis due to BD. We need to pay attention to side effects for the longer time.
This PDF is available to Subscribers Only